A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial Evaluating the Safety and Efficacy of KL130008 Capsule in Patients With Severe Alopecia Areata
Latest Information Update: 16 Aug 2022
At a glance
- Drugs KL-130008 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors Sichuan Kelun Pharmaceutical Research Institute
Most Recent Events
- 16 Aug 2022 New trial record